테스토스테론 보충 요법 시장 : 제품 유형별, 유효 성분별, 최종사용자별 - 세계 기회 분석과 산업 예측(2023-2032년)

Testosterone Replacement Therapy Market By Product Type, By Active ingredients, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,940,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,303,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계의 테스토스테론 보충 요법 시장 규모는 2022년에 19억 달러에 달하며, 2023-2032년에 CAGR 4.2%로 성장하며, 2032년에는 29억 달러에 달할 것으로 예측되고 있습니다.

테스토스테론 대체 요법은 낮은 테스토스테론 수치를 해결하기 위해 고안된 의료 개입입니다. 테스토스테론은 남성 생식 조직의 발달과 근육량, 골밀도 및 얼굴 털과 같은 남성 특성을 유지하는 데 중요한 역할을하는 중요한 호르몬입니다. 남성은 나이가 들어감에 따라 테스토스테론 수치가 자연적으로 감소하는 경향이 있으며, 피로, 성욕 감퇴, 근육량 감소 등 다양한 증상을 유발합니다. 테스토스테론 보충 요법은 주사, 패치, 젤, 피하 이식 펠릿 등의 방법으로 외인성 테스토스테론을 투여하는 것입니다. 그 목적은 테스토스테론 수치를 정상 범위로 회복하고 관련 증상을 완화하는 것입니다.

테스토스테론 보충 요법 시장의 성장은 성선기능저하증의 유병률 증가와 테스토스테론 수치 감소의 위험 증가와 관련된 비만, 당뇨병, 대사증후군과 같은 만성질환의 발생률 증가에 기인합니다. 성선기능저하증의 유병률은 최근 수년간 눈에 띄게 증가하여 테스토스테론 보충 요법 시장의 성장을 가속하는 중요한 요인으로 부상하고 있습니다. 성선기능저하증은 고환에서 테스토스테론이 제대로 생성되지 않는 것을 특징으로 하며, 특히 나이가 들면서 남성 인구의 상당수가 이 질환에 영향을 받습니다. 예를 들어 2021년 국립의학도서관의 보고에 따르면 중년 남성의 성선기능저하증 유병률은 2.1%-38.7%로 추정됩니다. 테스토스테론 대체 요법은 성선기능저하증으로 인한 호르몬 불균형에 대처하는 데 있으며, 의료 전문가들이 주로 선택하는 치료법입니다. 따라서 성선기능저하증 유병률 증가는 시장 성장을 가속할 것으로 예상됩니다.

또한 저 테스토스테론을 유발하는 비만과 당뇨병과 같은 만성질환의 발생률 증가는 시장 성장을 가속할 것으로 예상됩니다. 당뇨병, 비만, 심혈관 질환과 같은 만성질환은 전 세계에서 점점 더 널리 퍼지고 있으며, 호르몬 불균형, 특히 테스토스테론 수치 감소를 경험하는 개인의 급증에 기여하고 있습니다. 과학적 연구는 만성질환과 테스토스테론 생산 감소 사이의 직접적인 상관관계를 밝혀냈으며, 낮은 테스토스테론 수치를 치료하기 위한 효과적인 치료 중재를 찾는 환자층이 상당수 존재한다는 사실을 입증했습니다. 2023년 국립의학도서관의 보고에 따르면 남성 비만은 호르몬 및 생식기능 장애를 초래하는 호르몬 장애와 관련이 있는 것으로 보고되었습니다. 남성 비만과 관련된 성선 기능 저하증은 중등도에서 중증 비만 환자의 최대 45%에서보고되었습니다. 따라서 비만 및 당뇨병과 같은 만성질환의 발생률 증가는 테스토스테론 대체 요법 시장의 성장을 가속할 것으로 예상됩니다. 그러나 화학적 필링 및 광선 치료와 관련된 부작용이 시장 성장을 억제하고 있으며, American College of Cardiology Foundation의 2023년 보고서에 따르면 테스토스테론 대체 요법을받은 피험자에서 폐색전증, 치명적이지 않은 부정맥, 심방 세동, 급성 상해의 발생률이 높은 것으로 보고되고 있습니다.

테스토스테론 보충 요법 시장은 제품 유형, 활성 성분, 최종사용자, 지역별로 분류됩니다. 제품 유형에 따라 시장은 주사제, 외용제, 기타로 분류됩니다. 기타 제품 유형에는 경구용, 임플란트, 비강용 등이 있습니다. 활성 성분별로 시장은 테스토스테론 사이피오네이트, 테스토스테론, 테스토스테론 에난테이트, 테스토스테론 운데카네이트, 기타로 나뉩니다. 최종사용자에 따라 병원, 클리닉으로 나뉩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(일본, 중국, 호주, 인도, 한국, 기타 아시아태평양), 유럽(브라질, 콜롬비아, 아르헨티나, 기타 아시아태평양), 중동 및 아프리카(GCC, 남미, 북아프리카, 기타 중동 및 아프리카)로 나누어 분석합니다.

이해관계자 주요 이점

• 이 보고서는 2022-2032년 테스토스테론 대체 요법 시장 분석 시장 부문, 현재 동향, 추정 및 추세, 동향을 정량적으로 분석하여 우세한 테스토스테론 대체 요법 시장 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter의 다섯 가지 힘 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급업체와 공급업체의 네트워크를 강화할 수 있도록 구매자와 공급업체의 잠재력을 강조합니다.
• 테스토스테론 대체 요법 시장의 세분화를 자세히 분석하여 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계 테스토스테론 보충 요법 시장 동향, 주요 기업, 시장 부문, 용도 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

이 보고서에서 가능한 커스터마이징

• 규제 가이드라인
• 고객의 관심사에 따른 기업 개요 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 개요 확장 리스트
• 과거 시장 데이터
• 주요 기업의 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
  • 억제요인
  • 기회

제4장 테스토스테론 보충 요법 시장 : 제품 유형별

• 개요
• 주사제
• 외용제
• 기타

제5장 테스토스테론 보충 요법 시장 : 유효 성분별

• 개요
• 시피온산 테스토스테론
• 테스토스테론
• 에난트산 테스토스테론
• 운데칸산 테스토스테론
• 기타

제6장 테스토스테론 보충 요법 시장 : 최종사용자별

• 개요
• 병원
• 진료소

제7장 테스토스테론 보충 요법 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 콜롬비아
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • GCC
  • 남아프리카공화국
  • 북아프리카
  • 기타 중동 및 아프리카

제8장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• AbbVie Inc.
• Besins Healthcare SA
• Acerus Pharmaceuticals Corporation
• Amneal Pharmaceuticals Inc.
• Acrux Ltd.
• Endo International plc.
• Biote Medical LLC
• Insud Pharma S.L
• Marius Pharmaceuticals
• Pfizer Inc.

KSA

영문 목차

영문목차

The global testosterone replacement therapy market was valued at $1.9 billion in 2022, and is projected to reach $2.9 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.

Testosterone replacement therapy is a medical intervention designed to address low levels of testosterone. Testosterone is a crucial hormone responsible for the development of male reproductive tissues and the maintenance of male characteristics, such as muscle mass, bone density, and facial hair. As men age, testosterone levels tend to decline naturally, leading to various symptoms such as fatigue, reduced libido, and loss of muscle mass. Testosterone replacement therapy involves the administration of exogenous testosterone through methods such as injections, patches, gels, or pellets implanted under the skin. The goal is to restore testosterone levels to a normal range and alleviate associated symptoms.

The testosterone replacement therapy market growth is attributed rise in prevalence of hypogonadism and the rising incidence of chronic diseases such as obesity, diabetes, and metabolic syndrome, which are associated with an increased risk of low testosterone levels. The prevalence of hypogonadism has witnessed a notable rise in recent years, emerging as a significant driver for the growth of testosterone replacement therapy market. Hypogonadism, characterized by the insufficient production of testosterone in the testes, affects a considerable portion of the male population, particularly as they age. For instance, according to 2021 report by National Library of Medicine, it was estimated that the prevalence of hypogonadism in middle-aged and older men varies between 2.1% and 38.7%. Testosterone replacement therapy has become a primary choice for healthcare professionals in addressing the hormonal imbalances associated with hypogonadism. Thus, a rise in prevalence of hypogonadism is expected to drive the growth of the market.

In addition, rise in incidence of chronic diseases such as obesity and diabetes which causes low testosterone is expected to drive the market growth. Chronic diseases, including diabetes, obesity, and cardiovascular ailments, have become increasingly prevalent worldwide, contributing to a surge in individuals experiencing hormonal imbalances, particularly low testosterone levels. Scientific studies have established a direct correlation between chronic illnesses and reduced testosterone production, creating a substantial patient pool seeking effective therapeutic interventions to treat low testosterone levels. According to 2023 report by National Library of Medicine, it was reported that male obesity is linked to hormonal disturbances leading to impaired gonadal functions, both hormonal and reproductive. Male obesity-related hypogonadism has been reported in up to 45% of patients with moderate to severe obesity. Thus, rise in incidence of chronic diseases, such as obesity and diabetes, is expected to drive the growth of the testosterone replacement therapy market. However, side effects associated with the chemical peels and photo therapy restrain the growth of the market. According to the 2023 report by American College of Cardiology Foundation, it was reported that the incidence of pulmonary embolism, nonfatal arrhythmia, atrial fibrillation, and acute injury was higher in subjects who received testosterone replacement therapy.

The testosterone replacement therapy market is segmented on the basis of product type, active ingredient, end user, and region. By product type, the market is classified into injectables, topical, and others. Other product types include oral, implant, and intranasal formulations. By active ingredient, the market is divided into testosterone cypionate, testosterone, testosterone enanthate, testosterone undecanoate, others. By end user, it is segregated into hospitals, and clinics. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the testosterone replacement therapy market are AbbVie Inc, Besins Healthcare SA, Acerus Pharmaceuticals Corporation, Amneal Pharmaceuticals Inc., Acrux Ltd., Endo International Plc, Biote Medical, LLC, Pfizer Inc., Insud Pharma S.L, and Marius Pharmaceuticals. Key players have adopted acquisition as a key developmental strategy to improve the product portfolio of the testosterone replacement therapy market

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the testosterone replacement therapy market analysis from 2022 to 2032 to identify the prevailing testosterone replacement therapy market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the testosterone replacement therapy market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global testosterone replacement therapy market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

• Injectables
• Topical
• Others

By Active ingredients

• Testosterone Undecanoate
• Others
• Testosterone Cypionate
• Testosterone
• Testosterone Enanthate

By End User

• Hospital
• Clinics

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• AbbVie Inc.
• Besins Healthcare SA
• Acerus Pharmaceuticals Corporation
• Amneal Pharmaceuticals Inc.
• Acrux Ltd.
• Endo International plc.
• Biote Medical LLC
• Insud Pharma S.L
• Marius Pharmaceuticals
• Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: TESTOSTERONE REPLACEMENT THERAPY MARKET, BY PRODUCT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Injectables
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Topical
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: TESTOSTERONE REPLACEMENT THERAPY MARKET, BY ACTIVE INGREDIENTS

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Testosterone Cypionate
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Testosterone
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Testosterone Enanthate
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Testosterone Undecanoate
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Others
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country

CHAPTER 6: TESTOSTERONE REPLACEMENT THERAPY MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Clinics
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: TESTOSTERONE REPLACEMENT THERAPY MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Product Type
  • 7.2.3. Market size and forecast, by Active ingredients
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Product Type
    • 7.2.5.1.2. Market size and forecast, by Active ingredients
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Product Type
    • 7.2.5.2.2. Market size and forecast, by Active ingredients
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Product Type
    • 7.2.5.3.2. Market size and forecast, by Active ingredients
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Product Type
  • 7.3.3. Market size and forecast, by Active ingredients
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Product Type
    • 7.3.5.1.2. Market size and forecast, by Active ingredients
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Product Type
    • 7.3.5.2.2. Market size and forecast, by Active ingredients
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Product Type
    • 7.3.5.3.2. Market size and forecast, by Active ingredients
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Product Type
    • 7.3.5.4.2. Market size and forecast, by Active ingredients
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Product Type
    • 7.3.5.5.2. Market size and forecast, by Active ingredients
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Product Type
    • 7.3.5.6.2. Market size and forecast, by Active ingredients
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Product Type
  • 7.4.3. Market size and forecast, by Active ingredients
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Product Type
    • 7.4.5.1.2. Market size and forecast, by Active ingredients
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Product Type
    • 7.4.5.2.2. Market size and forecast, by Active ingredients
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Product Type
    • 7.4.5.3.2. Market size and forecast, by Active ingredients
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Product Type
    • 7.4.5.4.2. Market size and forecast, by Active ingredients
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Product Type
    • 7.4.5.5.2. Market size and forecast, by Active ingredients
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Product Type
    • 7.4.5.6.2. Market size and forecast, by Active ingredients
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. Latin America
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Product Type
  • 7.5.3. Market size and forecast, by Active ingredients
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Product Type
    • 7.5.5.1.2. Market size and forecast, by Active ingredients
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Colombia
    • 7.5.5.2.1. Market size and forecast, by Product Type
    • 7.5.5.2.2. Market size and forecast, by Active ingredients
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Argentina
    • 7.5.5.3.1. Market size and forecast, by Product Type
    • 7.5.5.3.2. Market size and forecast, by Active ingredients
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest of Latin America
    • 7.5.5.4.1. Market size and forecast, by Product Type
    • 7.5.5.4.2. Market size and forecast, by Active ingredients
    • 7.5.5.4.3. Market size and forecast, by End User
• 7.6. Middle East and Africa
  • 7.6.1. Key market trends, growth factors and opportunities
  • 7.6.2. Market size and forecast, by Product Type
  • 7.6.3. Market size and forecast, by Active ingredients
  • 7.6.4. Market size and forecast, by End User
  • 7.6.5. Market size and forecast, by country
    • 7.6.5.1. Gcc
    • 7.6.5.1.1. Market size and forecast, by Product Type
    • 7.6.5.1.2. Market size and forecast, by Active ingredients
    • 7.6.5.1.3. Market size and forecast, by End User
    • 7.6.5.2. South Africa
    • 7.6.5.2.1. Market size and forecast, by Product Type
    • 7.6.5.2.2. Market size and forecast, by Active ingredients
    • 7.6.5.2.3. Market size and forecast, by End User
    • 7.6.5.3. North Africa
    • 7.6.5.3.1. Market size and forecast, by Product Type
    • 7.6.5.3.2. Market size and forecast, by Active ingredients
    • 7.6.5.3.3. Market size and forecast, by End User
    • 7.6.5.4. Rest Of Mea
    • 7.6.5.4.1. Market size and forecast, by Product Type
    • 7.6.5.4.2. Market size and forecast, by Active ingredients
    • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. AbbVie Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Besins Healthcare SA
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Acerus Pharmaceuticals Corporation
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Amneal Pharmaceuticals Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Acrux Ltd.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Endo International plc.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Biote Medical LLC
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Insud Pharma S.L
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Marius Pharmaceuticals
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Pfizer Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료